Daniel Shelly
Chief Business Development Officer PolTREG
Dan Shelly is a member of the Executive Leadership Team at PolTREG/Immuthera, responsible for advancing next-generation T-regulatory cell therapies for autoimmune disease. Former VP of Business Development & Alliances at Prescient Therapeutics, supporting CAR-immune cell platforms and targeted therapies. Previously Director of Global Business Development at PATH and Co-Lead of its COVID-19 task force. Brings 19+ years of biopharma BD, licensing & alliance experience. Adjunct professor in the Masters in Clinical Drug Development program at University of Cincinnati College of Pharmacy.
Seminars
Scale Readiness Across Modalities
This invitation-only think tank designed exclusively for C-suite executives offers a rare opportunity to connect with cell therapy leaders across modalities and indications. Exchange perspectives, engage in depth discussions on the most pressing challenges, influence the direction of the field and gain strategic insights that extend beyond the summit.
